结核分枝杆菌宿主反应3基因检测在家庭接触者中的诊断与预后准确性:前瞻性纵向队列研究
在莫桑比克、坦桑尼亚和津巴布韦开展前瞻性纵向诊断与预后准确性研究,纳入2079名结核病家庭接触者,每6个月进行MTB-HR检测及结核筛查至24个月。MTB-HR未达2025 WHO筛查或预后目标产品标准,但阳性预测值高于现有检测。
要点
- 未达WHO目标产品标准,但阳性预测值优于现有检测
核心结论
- MTB-HR未达到2025 WHO目标产品标准中对筛查或预后用途的要求。
- MTB-HR对 incident tuberculosis 的阳性预测值高于目前使用的检测方法。
- 研究结果支持MTB-HR在筛查和预防策略中可能发挥作用。
研究设计与样本
- 前瞻性、纵向、诊断与预后准确性队列研究,在莫桑比克、坦桑尼亚和津巴布韦开展。
- 招募10岁及以上与确诊结核患者共同居住的家庭接触者,排除过去4周内使用过抗分枝杆菌抗生素者。
- 每6个月进行实时Cepheid Xpert MTB-HR检测及临床、影像学和微生物学结核筛查,随访至24个月。
- 结核诊断由终点评审委员会确定,采用受试者工作特征曲线下面积(AUROC)评估判别能力。
临床怎么用
- MTB-HR可作为结核家庭接触者筛查的辅助工具,其阳性预测值优于现有检测。
- MTB-HR阴性结果不能完全排除未来发病风险,需结合临床随访。
- 在资源有限社区环境中,MTB-HR可能有助于识别需要预防性治疗的高风险接触者。
局限性
- 研究未达到WHO目标产品标准,筛查和预后用途的准确性仍需优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis elimination is constrained by symptom-based and sputum-dependent diagnostic strategies, which miss asymptomatic disease and are difficult to deploy in community settings. Household contacts of people with tuberculosis are a priority population for screening and preventive therapy, but existing tests have poor prognostic ability. We aimed to evaluated host-response assays for screening and prognostic use in household contacts of people with tuberculosis. METHODS: In this prospective, longitudinal, diagnostic and prognostic accuracy study, we recruited people aged 10 years and older who lived with a person diagnosed with tuberculosis in Mozambique, Tanzania, or Zimbabwe. Household contacts who had taken antimycobacterial antibiotics within the past 4 weeks were excluded. Participants had real-time Cepheid Xpert Mycobacterium tuberculosis Host Response (MTB-HR) testing and clinical, radiological, and microbiological tuberculosis screening every 6 months for up to 24 months. The primary outcomes were the diagnostic accuracy of MTB-HR obtained within 30 days of a confirmed or likely tuberculosis diagnosis at any baseline or follow-up visit, and the prognostic ability of MTB-HR for incident tuberculosis using MTB-HR results obtained 1-6 months, 6-12 months, and 1-12 months before incident tuberculosis diagnosis. Tuberculosis diagnoses were established by an endpoint review committee and we assessed discrimination using the area under the receiver operating characteristic (AUROC) curve. The study was registered with ClinicalTrials.gov (NCT04781257) and is completed. FINDINGS: Between March 8, 2021, and March 23, 2023, we screened 2109 household contacts and enrolled 2079 for analysis (1294 [62·2%] female and 785 [37·8%] male). In the diagnostic analysis (41 household contacts with tuberculosis), the AUROC was 0·86 (95% CI 0·79-0·92). The prognostic analysis included 29 people with incident tuberculosis during the 1-6-month interval, 19 people for the 6-12-month interval, and 39 people for the 1-12-month interval, yielding AUROCs of 0·80 (0·71-0·89), 0·64 (0·53-0·76), and 0·71 (0·62-0·79), respectively, at optimised cutoffs. For the 6-month prediction at the optimised cutoff, the positive predictive value was 7·5% (95% CI 4·9-11·4). INTERPRETATION: MTB-HR did not meet the 2025 WHO target product profile criteria for screening or prognostic use; however, its positive predictive value for incident tuberculosis was higher than that of currently used tests. These findings support a potential role for MTB-HR in screening and prevention strategies. FUNDING: The second European and Developing Countries Clinical Trials Partnership (EDCTP2) programme.
引用
- Larsson L, Olaru ID, Behnke AL, et al. Diagnostic and prognostic accuracy of the Mycobacterium tuberculosis host response 3-gene cartridge among tuberculosis household contacts in Mozambique, Tanzania, and Zimbabwe: a prospective, longitudinal, diagnostic and prognostic accuracy cohort study. Lancet Infect Dis. 2026. PMID: 42026013. doi:10.1016/S1473-3099(26)00114-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。